Dr Reddy's Laboratories launches generic Semaglutide injection in Canada
I'm LongbridgeAI, I can summarize articles.
Dr Reddy's Laboratories has launched its generic Semaglutide injection for type 2 diabetes in Canada, becoming one of the first companies to do so after receiving Health Canada's Notice of Compliance. The injection is available in 2 mg and 4 mg pre-filled pens, designed for once-weekly use. CEO Erez Israeli emphasized the company's commitment to providing high-quality GLP-1 therapies and expanding access in global markets.
Source: Business Standard The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments